Desk Review and Recommendations for Private Sector Engagement
Journal of Infectious Diseases and Therapeutics, 2013, 1, 17-24
Application for Program Design in the Europe and Eurasia Region
No publication year indicated.
This study consists of a descriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015, being the first report of a genotypic testing used to provide information about second line drug resistance in Mozambique.
BMC Infectious Diseases (2016) 16:423 DO...I 10.1186/s12879-016-1766-x
more
The aim of this handbook is to provide guidance for trained anaesthetists working for the ICRC and to offer advice in areas where practice will differ from that in their home country. It is designed to supplement the practical training given in ICRC war-surgery seminars and to support the work of th...e ICRC in war surgery
more
The adoption and the entry into force of the Convention on the Rights of Persons with Disabilities and its Optional Protocol challenge such attitudes and mark a profound shift in existing approaches towards disability.
PLOS ONE | https://doi.org/10.1371/journal.pone.0196239 April 23, 2018
Journal of Social Aspects of HIV/AIDS VOL. 13 NO. 1 2016
To link to this article: https://doi.org/10.1080/17290376.2016.1226942
Nota INformatIva Nº 13/2020 - SE/GaB/SE/mS
September 2020
Guia rápido para profissionais de saúde
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more
Informe sobre poblaciones clave.